These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31959479)

  • 1. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
    Rossotti R; Tavelli A; Bonora S; Cingolani A; Lo Caputo S; Saracino A; Soria A; Marinaro L; Uberti-Foppa C; Mussini C; Puoti M; d'Arminio Monforte A
    Dig Liver Dis; 2020 Apr; 52(4):447-451. PubMed ID: 31959479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
    J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
    Xiao H; Chen J; Wang J; Li J; Yang F; Lu H
    Medicine (Baltimore); 2019 Jul; 98(30):e16524. PubMed ID: 31348267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus.
    Yunihastuti E; Amelia F; Hapsari AI; Wicaksana B; Natali V; Widhani A; Sulaiman AS; Karjadi TH
    Health Qual Life Outcomes; 2021 May; 19(1):154. PubMed ID: 34039353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
    BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Nagaty A; Helmy SH; Abd El-Wahab EW
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    Zhang M; O'Keefe D; Iwamoto M; Sann K; Kien A; Hang V; Brucker C; Jolivet P; Ly S; Chhit D; Balkan S; Marquardt T; Le Paih M; Dousset JP
    J Viral Hepat; 2020 Sep; 27(9):886-895. PubMed ID: 32358826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
    Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
    Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    Wahid B; Shami K; Joiya SA; Özuyar SEG; Idrees M
    J Med Virol; 2020 Dec; 92(12):3868-3870. PubMed ID: 32419178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
    Calvaruso V; Mazzarelli C; Milazzo L; Badia L; Pasulo L; Guaraldi G; Lionetti R; Villa E; Borghi V; Carrai P; Alberti A; Biolato M; Piai G; Persico M; Santantonio T; Felder M; Angelico M; Montalbano M; Mancusi RL; Grieco A; Angeli E; D'Offizi G; Fagiuoli S; Belli L; Verucchi G; Puoti M; Craxì A
    Sci Rep; 2019 Jan; 9(1):585. PubMed ID: 30679515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
    Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
    Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
    Dehghan Manshadi SA; Merat S; Mohraz M; Rasoolinejad M; Sali S; Mardani M; Tabarsi P; Somi MH; Sedghi R; Tayeri K; Nikbin M; Karimi J; Sharifi AH; Kalantari S; Norouzi A; Merat D; Malekzadeh Z; Mirminachi B; Poustchi H; Malekzadeh R
    Int J Clin Pract; 2021 Aug; 75(8):e14304. PubMed ID: 33930223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Saito Y; Imamura M; Uchida T; Osawa M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Serikawa M; Aikata H; Abe-Chayama H; Hayes CN; Chayama K
    J Med Virol; 2020 Feb; 92(2):210-218. PubMed ID: 31584207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.